Group 1 - The company plans to change its name from "启迪药业" to "古汉养生健康产业集团股份公司" to better reflect its main business and enhance brand recognition among consumers and investors [1] - The name change has been approved by the company's board of directors and will be submitted for regulatory approval, with the final name subject to market supervision department approval [1][2] - The company emphasizes that the name change will not significantly impact its current operating performance and is not intended to mislead investors [1] Group 2 - Founded in 1956, the company is the first listed pharmaceutical enterprise in Hunan Province and is recognized as a national key high-tech enterprise [2] - The company's core product, "古汉养生精," is derived from ancient Chinese medicine and is known for its health benefits, including energy replenishment and kidney nourishment [2] - In the first half of 2025, the company reported revenue of 142.4 million yuan, a year-on-year decline of 2.87%, while net loss improved by 26.61% to 17.17 million yuan [2]

Group 1 - The company announced the nomination of Jiang Xin and Zhou Yanqi as candidates for non-independent directors of the tenth board of directors [2]

Core Viewpoint - The company intends to change its name to better reflect its main business and industry characteristics, enhancing brand recognition among consumers and investors [1] Group 1 - The company announced a name change to "Gu Han Health Industry Group Co., Ltd." pending approval from market supervision authorities [1] - The decision was made during the 10th Board of Directors meeting held on September 4, 2025, with 5 votes in favor [1] - The company will also revise relevant clauses in its Articles of Association in conjunction with the name change [1] Group 2 - After the name change is completed, the company will apply for a change in its stock abbreviation according to Shenzhen Stock Exchange regulations, while the stock code will remain unchanged [1]

Group 1 - The core point of the announcement is the approval of the expected daily related transactions for the year 2025 by the company's supervisory board [1] - The related transactions involve the sale of pharmaceuticals and provision of production and research services to a related party, Hunan Hengchang Pharmaceutical Group Co., Ltd., by the company and its subsidiaries [1] - The transaction prices are based on market prices for similar businesses and are determined through friendly negotiations, ensuring fairness and reasonableness without adversely affecting the company's operations or harming the interests of minority shareholders [1] Group 2 - The supervisory board meeting was conducted in accordance with the Company Law and the company's articles of association, with all three participating supervisors voting in favor of the proposal [1] - The resolution received unanimous support with 3 votes in favor, 0 votes against, and 0 abstentions [1]

Group 1 - The company held a temporary board meeting where all five participating directors voted in favor of several key proposals [1][2][3] - The company plans to appoint Jiang Xin and Zhou Yanqi as non-independent directors, pending approval at the first temporary shareholders' meeting in 2025 [1][2] - The company intends to change its name to "Guhan Health Industry Group Co., Ltd." to better reflect its main business and enhance brand recognition [2][3] Group 2 - The company expects to engage in daily operational related transactions with its shareholder's affiliate, Hunan Hengchang Pharmaceutical Group Co., Ltd., with a total transaction amount not exceeding 50 million yuan in 2025 [2][3] - A temporary shareholders' meeting is scheduled for September 22, 2025, to discuss the aforementioned proposals [3][4] - All proposals from the board meeting require approval at the upcoming shareholders' meeting [4]

人民财讯9月5日电，启迪药业（000590）9月5日晚间公告，拟将公司名称变更为"古汉养生健康产业集 团股份公司"，并同步修订《公司章程》的相关条款。待公司名称变更完成后，公司将根据深交所有关 规定向其申请变更证券简称，公司证券代码保持不变。 ...

Core Viewpoint - The company intends to change its name to "Gu Han Health Industry Group Co., Ltd." and will revise relevant provisions in its Articles of Association following the name change [1] Group 1 - The company's board of directors has approved the name change [1] - The company will apply for a change in its stock abbreviation with the Shenzhen Stock Exchange after the name change is completed, while the stock code will remain unchanged [1]

Group 1 - The company intends to change its name to "Gu Han Health Industry Group Co., Ltd." [1] - The board of directors has approved the name change and the related amendments to the Articles of Association [1] - After the name change is completed, the company will apply for a change of its stock abbreviation while maintaining its stock code [1]

启迪药业公告，公司于2025年9月4日召开第十届董事会临时会议，审议通过了《关于拟变更公司名称并 修改〈公司章程〉的议案》，同意将公司名称拟变更为"古汉养生健康产业集团股份公司"（申请名称， 最终名称以市场监督管理部门核准为准），并同步修订《公司章程》的相关条款。待公司名称变更完成 后，公司将根据深圳证券交易所有关规定向其申请变更证券简称，公司证券代码保持不变。 ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-035 启迪药业集团股份公司 关于拟变更公司名称并修改《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 2、该事项尚需经公司股东大会审议通过，并向市场监督管理部门申请变更 登记 一、公司名称拟变更基本情况 （一）拟变更公司名称情况 2025 年 9 月 4 日，启迪药业集团股份公司（以下简称"公司"）召开第十届 董事会临时会议，以 5 票赞成审议通过了《关于拟变更公司名称并修改〈公司章 程〉的议案》，同意将公司名称拟变更为"古汉养生健康产业集团股份公司"（申 请名称，最终名称以市场监督管理部门核准为准），并同步修订《公司章程》的 相关条款。待公司名称变更完成后，公司将根据深圳证券交易所有关规定向其申 请变更证券简称，公司证券代码保持不变。 | 条款目录 | 现行公司章程 | | | 修订后的公司章程 | | | | --- | --- | --- | --- | --- | --- | --- | | 第四条 | 中文全称：启迪药业集团股份公司 | | | 中文全 ...